1 Biogenic Synthesis, Purification and Chemical Characterization of Anti-Inflammatory Resolvins Derived from Docosapentaenoic Acid (DPAn-6) Bindi Dangi 1 , Marcus Obeng 1 , Julie M. Nauroth 1 , Mah Teymourlouei 1,2 , Micah Needham 1 , Krishna Raman 1 , Linda M. Arterburn 1,3 From Martek Biosciences Corp. 1 , 6480 Dobbin Road, Columbia, Maryland, USA; U. S. Pharmacopeia 2 , 12601 Twinbrook Parkway, Rockville, MD 20852 ( present address) Alba Therapeutics Corp. 3 , 800 West Baltimore Street, Baltimore, MD 21201 (present address) Running Title: Resolvins from DPAn-6 Address Correspondence to: Bindi Dangi, Martek Biosciences, 6480 Dobbin Road, Columbia, MD 21045; Phone: 443-542-2148, fax-410-740-2985, email: [email protected]Enzymatically oxygenated derivatives of the omega-3 fatty acids DHA and EPA, known as resolvins, have potent inflammation resolution activity (1-5). Our objective was to determine whether similar derivatives are enzymatically synthesized from other C-22 fatty acids, and whether these molecules possess inflammation resolution properties. The reaction of DHA, DPAn-3 and DPAn-6 with 5-, 12-, and 15-lipoxygenases produced oxylipins which were identified and characterized by LC-MS/MS. DPAn-6 and DPAn-3 proved to be good substrates for 15-lipoxygenase. 15- lipoxygenase proved to be the most efficient enzyme of the three tested for conversion of LC-PUFAs to corresponding oxylipins. Since DPAn-6 is a major component of Martek DHA- S TM oil, we focused our attention on reaction products obtained from the DPAn-6 and 15- lipoxygenase reaction. 17(S)-hydroxy-DPAn-6 and 10,17(S)-dihydroxy-DPAn-6 were the main products of this reaction. These compounds were purified to 98% purity by preparatory HPLC techniques and further characterized by NMR, UV-spectrophotometry, and tandem mass-spectrometry. We tested both compounds in two animal models of acute inflammation and demonstrated that both compounds are potent anti-inflammatory agents that are active on local, intravenous as well as oral administration. These oxygenated DPAn-6 compounds can thus be categorized as a new class of DPAn-6 derived resolvins. Enzymatically formed oxygenation products of C-20 and C-22 LC-PUFAs (long-chain polyunsaturated fatty acids), have important biological roles in inflammation, allergies and blood clotting and are thus believed to have therapeutic potential in several chronic immune diseases (6-10) Several biologically important products of ARA (cis-5,8,11,14-eicosatetraenoic acid/arachidonic acid), EPA (cis-5,8,11,14,17- eicosapentaenoic acid) and DHA (cis- 4,7,10,13,16,19-docosahexaenoic acid) have been described (4,11,12). Pro-inflammatory oxylipins such as leukotrienes and some prostaglandins are derived from ARA, an omega-6 fatty acid. Interestingly, the same fatty acid also serves as a precursor to anti-inflammatory or pro-resolution molecules like lipoxins (13,14). Stable analogues of lipoxins are being developed as drugs for asthma and other inflammatory airway diseases (15,16). Oxylipins derived from omega-3 fatty acids such as DHA and EPA, known as resolvins, are primarily anti-inflammatory in nature (17). EPA acts as a precursor to the E-series resolvins that have shown potential in the treatment of colitis, arthritis and periodontitis (18-20). The resolvins of the D-series derived from DHA are useful as neuroprotective agents. 10,17-HDHA (10,17-dihydroxy-4,7,11,13,15,19- docosahexaenoic acid) or NPD1 (neuroprotectin D1) is a resolvin that is formed endogenously in the human brain and eye and is believed to exert its protective effect against cell injury-induced oxidative stress (21-23). The main enzymes responsible for the production of these oxygenated LC-PUFA products are primarily lipoxygenases, and in addition cyclo-oxygenases, and cytochromes P450. These enzymes produce oxylipins via transcellular activity, often involving multiple cell- types (24). This activity mainly results in mono-, di-, and tri-hydroxylation products of fatty acids that have varying potencies depending on the exact structure of the compound. Lipoxygenases are non-heme, iron containing dioxygenases that http://www.jbc.org/cgi/doi/10.1074/jbc.M809014200 The latest version is at JBC Papers in Press. Published on March 26, 2009 as Manuscript M809014200 Copyright 2009 by The American Society for Biochemistry and Molecular Biology, Inc. by guest on August 8, 2020 http://www.jbc.org/ Downloaded from
Transcript
1
Biogenic Synthesis, Purification and Chemical Characterization of Anti-Inflammatory Resolvins Derived from Docosapentaenoic Acid (DPAn-6)
Bindi Dangi1, Marcus Obeng1, Julie M. Nauroth1, Mah Teymourlouei1,2, Micah Needham1, Krishna
Raman1, Linda M. Arterburn1,3 From Martek Biosciences Corp.1, 6480 Dobbin Road, Columbia, Maryland, USA;
U. S. Pharmacopeia2, 12601 Twinbrook Parkway, Rockville, MD 20852 (present address) Alba Therapeutics Corp.3, 800 West Baltimore Street, Baltimore, MD 21201 (present address)
Running Title: Resolvins from DPAn-6 Address Correspondence to: Bindi Dangi, Martek Biosciences, 6480 Dobbin Road, Columbia, MD
Enzymatically oxygenated derivatives of the omega-3 fatty acids DHA and EPA, known as resolvins, have potent inflammation resolution activity (1-5). Our objective was to determine whether similar derivatives are enzymatically synthesized from other C-22 fatty acids, and whether these molecules possess inflammation resolution properties. The reaction of DHA, DPAn-3 and DPAn-6 with 5-, 12-, and 15-lipoxygenases produced oxylipins which were identified and characterized by LC-MS/MS. DPAn-6 and DPAn-3 proved to be good substrates for 15-lipoxygenase. 15-lipoxygenase proved to be the most efficient enzyme of the three tested for conversion of LC-PUFAs to corresponding oxylipins. Since DPAn-6 is a major component of Martek DHA-STM oil, we focused our attention on reaction products obtained from the DPAn-6 and 15-lipoxygenase reaction. 17(S)-hydroxy-DPAn-6 and 10,17(S)-dihydroxy-DPAn-6 were the main products of this reaction. These compounds were purified to 98% purity by preparatory HPLC techniques and further characterized by NMR, UV-spectrophotometry, and tandem mass-spectrometry. We tested both compounds in two animal models of acute inflammation and demonstrated that both compounds are potent anti-inflammatory agents that are active on local, intravenous as well as oral administration. These oxygenated DPAn-6 compounds can thus be categorized as a new class of DPAn-6 derived resolvins.
Enzymatically formed oxygenation products of C-20 and C-22 LC-PUFAs (long-chain polyunsaturated fatty acids), have important biological roles in inflammation, allergies and blood clotting and are thus believed to have
therapeutic potential in several chronic immune diseases (6-10) Several biologically important products of ARA (cis-5,8,11,14-eicosatetraenoic acid/arachidonic acid), EPA (cis-5,8,11,14,17-eicosapentaenoic acid) and DHA (cis-4,7,10,13,16,19-docosahexaenoic acid) have been described (4,11,12). Pro-inflammatory oxylipins such as leukotrienes and some prostaglandins are derived from ARA, an omega-6 fatty acid. Interestingly, the same fatty acid also serves as a precursor to anti-inflammatory or pro-resolution molecules like lipoxins (13,14). Stable analogues of lipoxins are being developed as drugs for asthma and other inflammatory airway diseases (15,16). Oxylipins derived from omega-3 fatty acids such as DHA and EPA, known as resolvins, are primarily anti-inflammatory in nature (17). EPA acts as a precursor to the E-series resolvins that have shown potential in the treatment of colitis, arthritis and periodontitis (18-20). The resolvins of the D-series derived from DHA are useful as neuroprotective agents. 10,17-HDHA (10,17-dihydroxy-4,7,11,13,15,19-docosahexaenoic acid) or NPD1 (neuroprotectin D1) is a resolvin that is formed endogenously in the human brain and eye and is believed to exert its protective effect against cell injury-induced oxidative stress (21-23).
The main enzymes responsible for the production of these oxygenated LC-PUFA products are primarily lipoxygenases, and in addition cyclo-oxygenases, and cytochromes P450. These enzymes produce oxylipins via transcellular activity, often involving multiple cell-types (24). This activity mainly results in mono-, di-, and tri-hydroxylation products of fatty acids that have varying potencies depending on the exact structure of the compound. Lipoxygenases are non-heme, iron containing dioxygenases that
http://www.jbc.org/cgi/doi/10.1074/jbc.M809014200The latest version is at JBC Papers in Press. Published on March 26, 2009 as Manuscript M809014200
Copyright 2009 by The American Society for Biochemistry and Molecular Biology, Inc.
catalyze the regioselective and enantioselective oxidation of polyunsaturated fatty acids containing one or more cis,cis-1,4-pentadienoic moieties to give the corresponding hydroperoxy derivatives (25,26). We thus considered that in addition to DHA and EPA, other C-22 PUFAs containing such methylene interrupted double-bonds may also be substrates for lipoxygenases, and that resulting products may have anti-inflammatory activity similar to DHA-derived resolvins. DPAn-6 (cis-4,7,10,13,16-docosapentaenoic acid) is present in algal oils and recent studies have demonstrated that this fatty acid has anti-inflammatory activities in vitro and in conjunction with DHA, also has anti-inflammatory activity in vivo (*see footnotes). Also, it has been suggested that a combination of DHA and DPAn-6 could be a beneficial natural therapy in neuroinflammatory conditions like Alzheimer’s disease. Specifically, in a 3xTg-AD mouse model of AD (Alzheimer’s disease), DPAn-6 was shown to reduce levels of early-stage phospho-tau epitopes, which in turn correlated with a reduction in phosphorylated c-Jun N-terminal kinase, a putative tau kinase (27). Although, the precise mechanism of action of DPAn-6 in these inflammatory milieus is not known, it suggests a possible role for oxylipin products of DPAn-6 in resolution of inflammation. Also, another LC-PUFA, DPAn-3 (cis-7,10,13,16,19-docosapentaenoic acid) usually present along with DHA and EPA in marine oils is known to be a potent inhibitor of platelet aggregation (28-30). In addition, this LC-PUFA has a potent inhibitory effect on angiogenesis through the suppression of VEGFR-2 (vascular endothelial-cell growth factor receptor 2) expression. Angiogenesis is known to contribute to tumor growth, inflammation, and microangiopathy again pointing to the possibility that anti-inflammatory activity of DPAn-3 might be mediated through resolvin-like products as in the case of DHA and EPA(31).
The purpose of this research was to determine whether oxylipins are formed from the C-22 LC-PUFAs, DPAn-6 and DPAn-3 by lipoxygenase activity, compare them to products formed from DHA, to chemically characterize products, purify key oxylipin products from the DPAn-6/15-lipoxygenase reaction and to test whether these compounds have resolvin-like anti-inflammatory activity. This research also sets the
stage for preparation and isolation of a wide range of other C-22 oxylipins that could be evaluated as potential anti-inflammatory compounds.
EXPERIMENTAL PROCEDURES Materials- 5-lipoxygenase from potato, 12-lipoxygenase from porcine leucocytes and 17(S)-HDHA (17(S)-hydroxy-4,7,10,13,15,19-docosahexaenoic acid) were from Cayman Chemicals (Ann Arbor, MI). TNFα (tumor necrosis factor-alpha) was from Peprotech, Inc. (Rocky Hill, NJ). All fatty acids were from Nu-Chek Prep (Elysian, MN). Filtration units were from Nalgene (Rochestor, NY). Acrodisc syringe filters were from Pall Life Sciences (Ann Arbor, MI). All Luna HPLC (high performance liquid chromatography) columns were from Phenomenex (Torrance CA), Chiralpak-IA from Chiral Technologies (West Chester, PA), Chirobiotic-T from Astec (Whippany, NJ) and all HPLC solvents were from Fisher Scientific (USA). All other reagents and materials were from Sigma-Aldrich (St. Louis, MO) while animals were from Harlan (Indianapolis, IN). Reaction of DHA, DPA(n-3) and DPA(n-6) with 15-lipoxygenase for comparison of efficiency of conversion- Soybean 15-lipoxygenase (Type 1-B) at a final concentration of 524 U/ml was mixed into 100 µM solutions of DHA, DPAn-6, or DPAn-3 fatty acids in 0.05 M sodium borate buffer, pH 9.0, and the reaction mixtures were incubated at 0 °C. Appearance of the mono-hydroxy conjugated diene derivatives of the fatty acids was monitored through absorbance at 237 nm. Conjugated diene products were quantified by UV spectrophotometry using an extinction coefficient of 28,000 /M.cm (32). Enzyme kinetics measurements of 15-lipoxygenase with DHA, DPA(n-3) and DPA(n-6) Type 1-B soybean lipoxygenase (39.8 U/ml) was used to dioxygenate substrates (DPAn-6, DPAn-3 and DHA at 5-100 µM) at 22 °C in oxygen saturated 0.05 M sodium borate buffer (pH 9.0) with 4.52 X 10-3 % (v/v) Tween 20. Final oxygen concentrations exceeded 750 mM, measured using a Clark-type oxygen electrode. The probe was calibrated by bubbling air and directly measuring the concentration with immobilized fluorescent ruthenium (OxySense 200T, OxySense, Dallas, TX). Approximately 38 s after enzyme addition,
the hydroperoxide product formation was monitored via UV absorbance at 236 nm (as described above) in 15 s intervals for 600 s (DU 800 Spectrophotometer, Beckman Coulter, Fullerton, CA). The read average time was 0.2 s. All experiments were repeated in triplicate. Product formation curves were smoothed with a negative exponential transform sampling all of the data with a power of ten calculating intervals every second. Product formation curves showed an initial lag period followed by a maximum in rate (rmax). While this is not the classical V0max, previous authors have shown it satisfies the steady-state assumption for application of the Michaelis-Menten kinetic model (33,34). This model, r=Vmax[S]/(Km+[S]), was used to elucidate the kinetic parameters. SigmaPlot 11.0 with the Enzyme Kinetic Module 1.3 (Systat Software, Inc., San Jose, CA) was used to perform the least squares fit of the aforementioned model. Reaction of DHA, DPAn-3 and DPAn-6 with 5-, 12- and 15-lipoxygenase for identification of reaction products- For the 5-lipoxygenase reaction, 200 µl of 10 U/µl potato 5-lipoxygenase was added to a 10-ml reaction mixture containing 100 µM fatty acid in 0.05 M Na-MES (2-(N-Morpholino)ethanesulfonic acid sodium salt) buffer, pH 6.3, 100 µM SDS (sodium dodecyl sulfate) and 0.02% C12E10 (Decaethylene glycol monododecyl ether). For the 12-lipoxygenase reaction, 100 µl of 0.75 U/µl porcine leukocyte-derived 12-lipoxygenase was added to a 10-ml solution containing 100 µM fatty acid in 0.1 M Tris-HCl (Tris(hydroxymethyl)aminomethane hydrochloride), pH 7.5, 5 mM EDTA (ethylenediamine-tetraacetic acid) and 0.03% Tween-20. For the 15-lipoxygenase reaction, 100 µl of 131 KU/ml soybean 15-lipoxygenase (Type 1-B) was added to a 10 ml reaction mixture containing 100 µM of fatty acids in 0.05 M sodium borate buffer, pH 9.0. Control reactions were run for all three enzymes under identical conditions without adding any enzyme. All reaction mixtures were stirred for 30 minutes at 4 ºC. Reaction products were reduced with sodium borohydride and acidified with glacial acetic before extraction on solid phase DSC-18 cartridges. Final elutions were done using anhydrous ethanol and reaction products analyzed by LC-MS/MS (liquid chromatography coupled
with tandem mass-spectrometry). The reaction of 15-lipoxygenase with DPAn-6 described above was scaled-up for the production of 17-HDPAn-6 (17-hydroxy-4,7,10,13,15-docosapentaenoic acid) and 10, 17-HDPAn-6 (10,17-dihydroxy-4,7,11,13,15-docosapentaenoic acid) from 1 gm of DPAn-6. Purification of 17-HDPAn-6 and 10,17-HDPAn-6- All purifications were carried out at a flow rate of 47 ml/min at room temperature on a Luna C18 (2), 10 µ, 100 Å, 50 mm X 250 mm column, setup on an Agilent 1200 preparatory HPLC unit, equipped with a diode array detector. The purification method involved elution with a mixture of solvents A and B. Solvent A consisted of 70% water, 30% methanol and 0.2% ammonium acetate and solvent B consisted of 100% acetonitrile. The method used for elution of compounds was 48% B at 0 mins, 48% B at 25 mins, 90% B at 35 mins, 90% B at 50 mins, 48% B at 52 mins and 48% B at 65 mins. Chromatograms were monitored simultaneously at 236 nm and 270 nm and fractions corresponding to peaks of interest were collected and pooled from several runs. Purity of fractions was monitored by UV spectrophotometery as well as by LC-MS. Fractions were concentrated using a rotary-evaporator and compounds extracted with ether. Ether extracts were concentrated and treated with anhydrous sodium sulfate to remove any traces of water. This solution was then filtered using Acrodisc syringe filters (Bulk Acrodisc CR 13 mm with 0.2 µM PTFE membrane, HPLC certified). Purity was ascertained by LC-MS and LC-MS/MS UV Spectrophotometry- UV spectrophotometry was carried out on either an Agilent 8453 (Agilent Technologies, Santa Clara, CA) or a Cary 4000 UV-Vis spectrophotometer (Varian Inc., Palo Alto, CA) or a DU800 Spectrophotometer ( Beckman Coulter, Fullerton, CA) . Extinction Coefficients of 17-HDPAn-6 and 10,17-diHDPAn-6 were determined in ethanol. LC-MS and LC-MS/MS- All routine reaction and purity analysis was done on a Hewlett Packard model 1100 liquid chromatography instrument interfaced with an electrospray ionization mass elective detector. Tandem MS/MS analysis of the products of the reactions of fatty acids and different lipoxygenases was performed on an Agilent 1100 Series HPLC Instrument (San Paulo, CA USA) interfaced with an Esquire 3000 ion trap
mass spectrometer equipped with electrospray ionization source (Bruker Daltonics, Billerica MA USA), or on an Agilent 1200 Series HPLC instrument interfaced with an Agilent LC/MSD Trap XCT Plus (San Paulo, CA USA). Mass spectrometers were operated in negative ion detection mode. Nitrogen was used as nebulizing and drying gas with nebulizer pressure at 20 p.s.i. and drying gas flow rate of 7 L/min. The interface temperature was maintained at 330 ºC. The chromatographic separation was carried out on a LUNA C18(2) column (250 x 4.6 mm, 5 µ, 100 Å) using the same mobile phase described for purification of the compounds under similar conditions at a flow rate of 0.4 ml/minute. NMR (nuclear magnetic resonance) experiment- All NMR experiments were conducted by NMRServices, Rochestor, NY. 25-50 milligrams of 17-HDPAn-6 or 10, 17-HDPAn-6 was dissolved in CDCl3 and used for NMR data acquisition. All NMR data were acquired at 298 ºK on a Bruker model, Avance spectrometer operating at 500 MHz Proton NMR frequency. 1D-1H, 1D-13C (1H-decoupled), 2D-1H-1H COSY (correlation spectroscopy), 2D-1H-1H DQFCOSY (double-quantum-filtered correlation spectroscopy), 2D-1H-13C-HSQC (heteronuclear single quantum coherence), 2D-1H-13C-HMBC (heterononuclear multiple bond-correlation) NMR data were acquired for 17 HDPAn-6. 1D-1H, 1D-13C (1H-decoupled), 2D-1H-1H COSY were acquired for 10,17-HDPAn-6. All data was processed using Bruker software and NMR spectra predictions were done using ChemDraw Ultra 10.0 and ACDlabs software. Chirality- 17-HDHA was prepared the same way as 17-HDPAn-6 except that DHA was used as a substrate. Either 17-HDHA or 17-HDPAn-6 was converted to 17-oxo-derivatives by dissolving 15 mg of each compound in anhydrous dichloromethane and then oxidizing the compounds at 0 ºC with 15 mg of Dess-Martin’s reagent. The 17-oxo-derivatives were then reduced using sodium borohydride to give the corresponding racemic mixtures. The racemic mixtures were then separated on a Chiralpak-IA column using methanol/water (80:20) as the mobile phase at a flow rate of 0.6 ml/min. at 25 ºC. The peaks were assigned as R or S by using 17(S)-HDHA as a reference standard. The same protocol was followed for 17-HDPAn-6 and the
order of elution of the two isomers was assumed to be the same as for 17-HDHA isomers. The Chirobiotic-T column was tested with supplier-recommended mobile phases. VCD (vibrational circular dichroism) studies were carried out by Biotools Inc. (Syracuse, NY) for 17-HDPAn-6. logDpH7.4 and Solubility- LogDpH7.4 and solubility studies were conducted by Cerep (Seattle, WA). All predictions of various physicochemical parameters were made using ACDLabs Software. logP was calculated based on the formula logP=logD+(pH-pKa) (35) Aqueous solubility (µM) was determined by comparing the peak area of the principal peak in a calibration standard (200 µM) containing organic solvent (methanol/water, 60/40, v/v) with the peak area of the corresponding peak in a buffer sample. Reference compounds used for comparing solubility were diethylstilbestrol, haloperidol, ketoconazole, metoprolol tartrate, phenytoin, rifampicin, simvastatin and tamoxifen. logDpH7.4 was determined by the shake-flask method using octanol and PBS pH 7.4 (35). The total amount of compound was determined as the peak area of the principal peak in a calibration standard (100 µM) containing organic solvent (methanol/water, 60/40, v/v). The amount of compound in the buffer was determined as the combined, volume corrected and weighted areas of the corresponding peaks in the aqueous phases of three organic–aqueous samples of different composition. An automated weighting system was used to ensure the preferred use of raw data from those samples with well quantifiable peak signals. The amount of the compound in the organic phase was calculated by subtraction. Subsequently, logD was calculated as log10 of the amount of compound in the organic phase divided by the amount of compound in the aqueous phase. Chemical Stability Studies- 17-HDPAn-6 and 10,17-HDPAn-6 were incubated at a concentration of 10 µM in both PBS and ethanol at 4 ºC for 14 days and at 22 ºC for 24 hours and at 37 ºC for two hours and peak heights were monitored by LC/MS/MS. For the 14 day stability studies, samples were analyzed at 0, 2, 4, 7, 9, 11 and 14 days. Samples were analyzed at 0 and 24 hours for the 22 ºC study and at 0 and 2 hours for the 37 ºC study. Animal Studies. All animal studies were performed in accordance with the Guide for the
Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health and/or the Final Rules of the Animal Welfare Act Regulation (9CFR). Mouse Air Pouch Study. To generate the dorsal air pouches, 6-8 wk-old female C57Bl/6N mice were anesthetized and 6 ml of sterile air was injected subcutaneously in the back (36). Pouches were re-inflated with 3 ml of sterile air 3 days later. Six days after initial pouch formation, 100 ng of the DPAn-6 oxylipin test compounds or 17 (S)-HDHA were administered to 10 animals per group in 1 ml of PBS, pH 7.4 (~0.005 mg/kg) by intrapouch injection. Within 5 min of compound administration, 100 ng of TNFα in 0.1 ml PBS was injected into the pouches to initiate an inflammatory response. Indomethacin was administered i.p. (intraperitoneally) at 2 mg/kg 30 min prior to the TNFα challenge as a positive control. Four hours after the TNFα challenge, pouch exudates were harvested, and leukocytes in the exudates were counted. A sampling of exudate cells from each animal was centrifuged onto microscope slides, and the cells were air dried and Geimsa stained to quantify granulocyte and mononuclear leukocytes. Rat Hind Paw Edema Studies. Hind paw edema studies were conducted on male Sprague-Dawley rats (170-200 g, 6-8 animals per group) using crosslinked lambda carrageenan as the inflammatory stimulus(37). Researchers were masked to the treatment groups in all hind paw studies. The first experiment involved administering DPAn-6 derived resolvins either intravenously (5 µg/animal, ~ 0.025 mg/kg) in the tail vein in 0.1 ml PBS 2 minutes prior to carrageenan challenge or p.o. (by oral gavage) in up to 4 ml of PBS ( 25 µg/animal, ~ 0.125 mg/kg) 30 minutes prior to carrageenan challenge. Indomethacin (5 mg/kg administered i.p. 30 min prior to challenge) and biogenically synthesized 17(S)-HDHA (5 µg/animal administered i.v. (intravenously) 2 min prior to challenge) served as positive and DHA resolvin controls respectively in this experiment. Rats were injected with 0.1 ml of 10 mg/ml carrageenan solution (prepared in water at least two weeks in advance of the experiment) in the subplantar region of the right hind paw. Paw volumes were measured by water
volume displacement at 0, 2, 4, 6 and 24 hrs post carrageenan challenge. The second experiment involved evaluating oral-dose response behavior of the two DPAn-6 resolvins. All compounds including the controls, were administered by oral gavage (4 ml per animal) 30 minutes prior to the carrageenan challenge. The two DPAn-6 oxylipins were diluted in PBS, pH 7.4 and dosed at 2.5, 25 and 250 µg/animal (approximately 0.0125, 0.125, 1.25 mg/kg body weight) and the biogenically-synthesized resolvin control 17-HDHA was given at a single dose of 25 µg/animal (0.125 mg/kg). Indomethacin was administered at 6 mg/animal (30 mg/kg). Carrageenan was administered as in the first rat hind-paw experiment. Paw edema volume was measured 2, 4 and 6 hrs after the carrageenan challenge. . Paw edema volume was calculated by subtracting right paw volume just prior to carrageenan injection from the post carrageenan-treated volume of the same paw. Statistical Analyses. Statistical analyses for animal studies were conducted in GraphPad Prism Version 4 (San Diego, CA) using Student’s t tests or ANOVA with Dunnett’s post test to compare treatment groups with control. Data are presented as means ± SD.
RESULTS Substrate Comparison with 15-
lipoxygenase- Figure 1 shows percent conversion of DHA, DPAn-3 and DPAn-6 upon treatment with soybean lipoxygenase at 0 ºC. As can be seen, under these conditions, 100% of DPAn-6 was efficiently converted to its conjugated diene derivative, whereas about 85% of DPAn-3 and 50% of DHA were converted to their respective conjugated diene derivatives by 15-lipoxygenase. These results were also corroborated by LC/MS peak analysis which showed that under these conditions, a single product with a conjugated diene was formed and this corresponded to the 17-hydroperoxy derivative in all three cases. In addition we also assessed enzyme kinetics parameters of the three substrates with 15-lipoxygenase at 22 ºC. Figure 2. shows the enzyme kinetics data with curve fits, and Table 1. shows the kinetic parameters. Over the substrate concentrations analyzed, the kinetic behavior was Michaelis-Menten. Although, DPAn-3 exhibited the highest value for Vmax, the efficiency with
which the enzyme converted DPAn-6 to products was higher than that for DHA and DPAn-3.
Products formed on reaction of fatty acids with 5-, 12- and 15-lipoxygenase- Tables 2, 3 and 4 give a summary of products formed when DHA, DPAn-3 and DPAn-6 are reacted with the various lipoxygenases. In all cases, the enzymes produced hydroperoxy compounds which were then reduced non-enzymatically by sodium borohydride to the corresponding hydroxy compounds. The hydroperoxy derivatives (data not shown) were detected in non-reduced reactions by LC-MS/MS techniques. Final reduced products were identified based on parent ion masses and diagnostic fragments. MS spectra of all monohydroxy compounds showed [M-H], [M-H]-H2O, [M-H]-CO2, [M-H]-CO2,-H2O which were 345, 327, 301, 283 respectively for monohydroxy-DPAn-6 and -DPAn-3 derivatives and were 343, 325, 299, 281 for monohydroxy-DHA derivatives. MS spectra of all dihydroxy-compounds showed [M-H], [M-H]-H2O, [M-H]-CO2, [M-H]-CO2,-H2O, [M-H]-2H2O, [M-H]-CO2,-2H2O which were 361, 343, 317, 325 and 281 respectively for dihydroxy-DPAn-3 and DPAn-6 derivatives and were 359, 341, 315, 323 and 279 for dihydroxy-DHA derivatives. All diagnostic fragments which help in ascertaining positions of oxygenation are outlined in Tables 2, 3 and 4. Of all the enzymes tested, 15-lipoxygenase was the most efficient in converting fatty acids to oxylipins, while 5-lipoxygenase and 12-lipoxygenase converted less than 10 % of the fatty acids to oxylipin-like compounds. Overall, many of the products characterized upon using DPAn-6 or DPAn-3 as substrates were similar to those obtained from DHA as reported earlier (1,3,5). As expected, the 15-lipoxygenase products were primarily oxygenated at the C-17 position ultimately producing 17-HDHA, 17-HDPAn-6 and 17-HDPAn-3, from the respective fatty acids. These compounds had a conjugated diene structure, with an absorbance maximum between 234-238 nm. In addition, 10,17-dihydroxy and 7,17-dihydroxy derivatives were produced from all three fatty acids. The 10,17-dihydroxy derivatives had an absorbance maximum at 270 nm with characteristic shoulders at 260 and 280 nm ( ± 2 nm), which are characteristic of a conjugated triene structure. The 7,17-dihydroxy derivatives had an absorbance maxima at ~ 242 nm ( ± 2 nm),
characteristic of two conjugated dienes interrupted by a methylene group. The main product (> 90%) formed on reacting 12-lipoxygenase with fatty acids was the 14-hydroxy derivative (hydroxylation at the ω-9 position) in all three cases. In addition, several other mono as well as dihydroxy derivatives were detected (see Table 3). When 5-lipoxygenase was used, the main product (> 90 %) formed was due to oxygenation at the ω-13 position resulting in the 10-hydroxy derivative. Other products were also seen (see Table 4). The 10,20-dihydroxy derivative was formed only from DHA and DPAn-3 and not from DPAn-6, since DPAn-6 lacks a double bond at C-19. None of the controls for any of the enzymatic reactions showed any appreciable levels of oxylipins, suggesting that there was no appreciable amount of non-enzymatic auto-oxidation under the conditions tested.
Gram-Scale Synthesis and Purification of 15-lipoxygenase DPAn-6 Resolvins- Figure 3 shows the LC profiles of products obtained, when 1 gm of DPAn-6 was reacted with 15-lipoxygenase. The main products that were formed were 17-HDPAn-6 (~ 85%), 10,17-HDPAn-6 (~ 4%) and 7,17-HDPAn-6 (~ 2%) similar to what is described above for the small-scale reaction. In addition, several other dihydroxy compounds (retention time 12-21 minutes), trihydroxy (retention time 5-10 minutes) derivatives as well as oxo and epoxide compounds (retention time 33-36 minutes) were produced. These were detected based on characteristic fragmentation patterns as well as UV behavior. For example, the 17-oxo-DPAn-6 showed a UV peak at 280 nm, with a [M-H] of 343 and a diagnostic fragment at 245 along with all other expected fragments. Similarly, the 16,17-epoxide of DPAn-6 exhibited no UV absorbance between 220 and 350 nm and showed the expected [M-H], [M-H]-H2O, [M-H]-CO2, [M-H]-CO2,-H2O fragments along with 233, 245, 274, 261 which are characteristic of an epoxide at the 16, 17 position. The total fraction accounted for by all these other compounds was less than 5 % of the main products formed.
Purification of 17-HDPAn-6 and 10,17-diHDPAn-6 resulted in > 98% pure compounds (Figure 4) that were further characterized and then used for other studies.
Structural Characterization of 17-HDPAn-6 and 10,17-diHDAPn-6- As described
previously, 17-HDPAn-6 showed a UV spectrum with an absorbance maximum at 236 nm. The extinction coefficient in ethanol at room temperature was calculated to be 30,000 /M.cm. All MS/MS fragments were consistent with the 17-HDPAn-6 structure as shown in Figure 4. Figure 5 shows the 1D-1H, 1D-13C and the 2D-1H,1H COSY spectra of 17-HDPAn-6. The number of peaks, integration and chemical shifts in both the 1D-1H and the 1D-13C spectra were consistent with the molecular formula C22H34O3 and were consistent with spectra predicted by Chemdraw and ACDlabs software. The 2D-1H,1H-COSY unambiguously showed that hydroxylation was at the 17 position. The protons belonging to C(17)-H-OH centered at 4.12 p.p.m. produced cross-peaks to C(16)-H and C(18)-H, but not with protons belonging to C(13) or C(14). A 2D 1H,1H-DQFCOSY, a 2D 1H,13C-HSQC and a 2D 1H,13C-HMBC confirmed all non-overlapping 1H and 13C assignments and double-bond configurations. The double bond configurations were confirmed based on several lines of evidence as outlined below. Butovich et al. have described signature chemical shifts obtained from NMR spectra of several compounds that are indicative of a trans-trans configuration (38,39). Specifically, a conjugated E,E-diene fragment would have produced a quartet with a chemical shift δ of 6.15 to 6.24 p.p.m. and this signature quartet is clearly absent in all spectra of the 17-HDPAn-6 produced in this study (See Figure 5) Coupling constant information also suggests that the structure is 17-hydroxydocosa-4Z, 7Z, 10Z, 13Z, 15E-pentaenoic acid. This is based on the fact that the value of J13,14 is 11 Hz, indicative of the cis-configuration around this vinyl group, whereas, J15,16 is ~15 Hz, again clearly indicating that the configuration around these double bonds is trans. In addition a comparison of chemical shifts of 17-HDPAn-6 with 17-HDHA produced by Butovich et al. are remarkably similar indicating similar double bond configurations (38).
10, 17-HDPAn-6 produced and purified to 98% homogeneity had a UV spectrum with a λmax at 270 nm and shoulders at 260 and 280 nm (±1 nm) indicative of a conjugated triene in the molecule (Figure 4). The extinction coefficient was estimated to be 38,000 /M.cm. The parent ion mass with m/z of 361 along with fragments (Figure 4), confirms hydroxylation at C-10 and C-
17 of DPAn-6 and is consistent with the molecular formula C22H34O4. NMR data for this compound is shown in Figure 6. The 1D-13C spectrum clearly shows the presence of 22 carbons with two of the carbons having a chemical shift δ of 71.62 p.p.m. and 71.02 p.p.m., indicative of hydroxylations at these two carbons. Again, as in the case of 17-HDPAn-6, no peaks with chemical shift δ at 6.12-6.24 p.p.m. were seen which would have indicated the presence of either 11E, 13E, 15Z or 11Z, 13E, 15E or 11E, 13E, 15E isomers. The 1H and the 13C chemical shifts and coupling constants were similar to those of potato-lipoxygenase derived as well soybean-lipoxygenase derived 10,17-dihydroxydocosahexa-4Z, 7Z, 11E 13Z, 15E, 19Z-enoic acid for C(1)-C(18) and H(1)-H(18) (38,39). Coupling constants of 15 Hz for trans-, and 10 Hz for cis double bond configurations were observed around the triene structure strongly suggesting that the compound was 10,17-dihydroxydocosa-4Z, 7Z, 11E, 13Z, 15E-pentaenoic acid. Although NMR data strongly suggests double bond configurations as described above, synthetic standards with known double-bond configurations will be needed for final confirmation.
Chirality- VCD techniques which are used for ascertaining absolute configurations at chiral centers were not successful in determination of chirality in the case of 17-HDPAn-6. Therefore, chiral chromatography was used for assigning chirality. Order of elution of R and S isomers on chiral columns is the same for similar hydroxylated-LC-PUFA compounds when the same chromatographic conditions are used (40,41). In this case, the 17-HDHA racemate mixture and 17(S)-HDHA was used to ascertain order of elution. The Chirobiotic-T column was not successful in separating isomers and final separations were successful using the Chiralpak-IA column. As seen in Figure 7, it is clear that the R isomer of 17-HDHA elutes before the S isomer. A similar separation for 17-HDPAn-6 shows that this enzymatically prepared compound comprises 95% S isomer and 5% R isomer. Hence, 15-lipoxygenase is primarily pro-S-selective in the case of DHA as well as DPAn-6 at the C-17 position.
Physicochemical properties and Stability- pKa values of both compounds were predicted by ACDlabs software to be 4.58. LogDpH7.4 values determined using PBS and octanol partitioning
were consistent with those predicted using ACDlabs software (Figure 8A) and were 3.5 for 17-HDPAn-6 and 2.7 for 10,17-diHDPAn-6. The corresponding calculated logP values were 6.32 and 5.09 respectively. Experimentally, solubility of both compounds in PBS, pH 7.4 was found to be more than 200 µM. Solubilities of reference compounds as determined in the same assay were 5.6 µM for diethylstilbestrol, 46.3 µM for haloperidol, 109.2 µM for ketoconazole, 227.3 µM for metoprolol tartrate, 81 µM for phenytoin, 197.8 µM for rifampicin, 19.9 µM for simvastatin and 0.6 µM for tamoxifen. Predictions using ACDlabs software (Figure 8B) suggest that 17-HDPAn-6 has a solubility of 1.9 mM and that the more polar 10,17-diHDPAn-6 has a solubility that is about six-fold higher at 12.2 mM in PBS, pH 7.4. Stability of compounds was tested in PBS and ethanol as described in Experimental Procedures. At 4 ºC, there was not more than 4% degradation after 14 days. Also, both compounds were completely stable (0% degradation) for 24 hours at room temperature and for 2 hours at 37 ºC. Anti-inflammatory activity of DPAn-6 resolvins in the air-pouch model- The murine dorsal air pouch model, mimicing acute inflammation of the synovium, was used to assess anti-inflammatory activity of DPAn-6 resolvins. Resolvins were administered locally by intrapouch injection, and within 5 min, TNFα was injected directly into the pouch to induce the inflammatory response. Exudates were harvested 4 hr later and infiltrating leukocytes were enumerated. Fig. 9 shows the total number of leukocytes in the pouch exudates. As expected, TNFα stimulated an approximately 4-fold increase in leukocyte migration into the pouch. Cell migration was reduced to the level of the negative control (no TNFα stimulation) by both 17-HDPAn-6 and 10,17-HDPAn-6, whereas the resolvin control 17(S)-HDHA tended to reduce migration, but the reduction was not statistically significant. The major effect of the DPAn-6-derived resolvin compounds was to reduce the proportion of granulocytes and increase the proportion of macrophages (Table 5) in the exudates, suggesting a switch from active immune response (granulocyte dominated) to resolution (macrophage dominated) of the inflammatory response. The two DPAn-6 resolvin compounds
administered locally at a dose of approximately 0.005 mg/kg (on a whole animal basis) were as efficacious as indomethacin administered intraperitoneally at a dose of 2 mg/kg in this study.
Rat hind-paw edema assay- The two DPAn-6 resolvins were tested in a rat carrageenan-induced hind paw edema model to confirm their anti-inflammatory activity in a second animal species and in a second in vivo model of acute inflammation. This also served to explore efficacy following systemic rather than local administration. The i.v. doses in this study were 50-fold higher than in the murine air pouch study to account for the larger species size and to account for systemic rather than local administration. Oral doses were an additional 5-fold higher than i.v. doses to help compensate for possibly lower bioavailability. Results, shown in Fig. 10 indicate that both 17-HDPAn-6 and 10,17-H DPAn-6 reduced edema volume following i.v. administration and resulted in approximately 20-25% reduction in paw edema at the 2, 4 and 6 hour time points, demonstrating activity of these compounds for at least 6 hours after i.v. administration. Potency was similar to the known resolvin 17-HDHA at 4 and 6 hrs, although the 17-HDHA appeared more potent at the 2-hr time point. There was no effect of any compound, including indomethacin, at the 24-hr time point. The 10,17-HDPAn-6 was active orally, resulting in similar reductions in edema as with the i.v. dosing of this compound. The 17-HDPAn-6 did not show activity at this dose following oral administration in this study. A second hind paw edema study was conducted to explore the dose response relationship of orally-administered DPAn-6 resolvins. Data from this study are summarized in Fig. 11. The responses in this dose-response assay reproduced the results from the first hind-paw assay in that the 25 µg-dose, 10,17-HDPAn-6 produced a significant approximately 20% reduction in paw edema, whereas the same dose of the 17-HDPAn-6 had no effect. The response to the resolvin 17-HDHA at 25 µg resembled that of 17-HDPAn-6 with no reduction in edema volume, whereas the indomethacin reduced swelling by about 30%. Although there was no effect of 17-HDPAn-6 at the mid (25 µg) dose, the low (2.5
µg) and high (250 µg) doses reduced edema at the 4-hr time point (Fig. 11C). The high dose of 17-HDPAn-6 was most effective and consistently reduced edema at all time points (Fig 11A). On the other hand, the mid dose of 10,17-HDPAn-6 was most effective at reducing edema at all time points (Fig. 11B). The low and high doses of this compound reduced edema at the 2-hour but not later time points. Both DPAn-6 resolvin compounds resulted in non-monotonic dose responses (Fig. 11C).
DISCUSSION Lipoxygenases catalyze the dioxygenation
of LC-PUFAs containing cis,cis,-1,4-pentadiene moieties (26). The primary site of oxidation in arachidonic acid is commonly used in naming these enzymes. For example, 15-lipoxygenase catalyzes the production of 15-hydroperoxyarachidonic acid from ARA (42). In the current study 15-lipoxygenase, 12-lipoxygenase and 5-lipoxygenase acted on DHA, DPAn-6 and DPAn-3 with positional preferences for dioxygenation. 15-lipoxygenase, primarily oxygenated the C22-substrates at C-17 or ω−6 as would be expected from previous studies with these enzymes, (3,4,43). In addition, 10,17- and 7,17-dihydroxy oxylipins were also obtained from DPAn-6 and DPAn-3. These compounds are analogous in structure to the potent anti-inflammatory 17-hydroxy series docosanoids described by Hong et al. (3). Other lipoxygenases like 12-lipoxygenase primarily oxygenated DHA, DPAn-3 and DPAn-6 at C14/ω−9 position and 5-lipoxygenase at the C-10 position, consistent with what was expected (4,44-46).Like DHA, other LC-PUFAs such as DPAn-6 and DPAn-3 and lipoxygenases are found in varying amounts in blood and several tissues, suggesting that these or other DPA-derived resolvins could be produced physiologically and act as bioactive mediators (47-52). However, actual biological production of these DPAn-6 derived resolvins remains to be investigated. Comparison of substrate reactions with 15-lipoxygenase at 0 ºC showed that DPAn-6 was completely converted to products whereas DHA and DPAn-3 were not, thus indicating that at such low temperatures DPAn-6 reacts with 15-lipoxygenase in a facile manner. When enzyme kinetics behavior was probed at higher temperatures (22 ºC) in the presence of a
surfactant, DPAn-3 exhibited the highest Vmax. However DPAn-6 proved to be the substrate that was converted most efficiently to products. The 15-lipoxygenase-PUFA reaction is a complex one, involving several phenomena such as substrate inhibition, product inhibition, product activation, substrate deactivation from decoupling of the radical substrate prior to oxygen insertion, low oxygen concentration and enzyme thermodynamic inactivation. Additionally, the substrates exhibit tendencies toward micelle formation on which 15-lipoxygenase does not act effectively (33). The c.m.c. (critical micelle concentration) for linoleic acid at pH 9.0 and 20 °C is 150 µM (53), and the c.m.c. for DHA at pH 8.8 and 25°C is 60-90 µM (54). Although some of the factors mentioned above were taken into consideration while determining kinetic constants, it was not feasible to evaluate all of them as is true for almost all studies evaluating the 15-lipoxygenase-PUFA reaction. Therefore the experiments reported here are useful for comparing the efficiency with which soybean 15-lipoxygenase converts DHA, DPAn-3 and DPAn-6 to products, but comparison to other studies, remains difficult, due to the large variability of conditions reported in literature. Both DHA and DPAn-3 are omega-3 fatty acids and the different kinetic behavior observed for DPAn-6 could be due to the fact that it is an omega-6 fatty acid. This could affect the affinity of the substrate to the enzyme at the reactive site, as well as at the site responsible for substrate inhibition. In absence of precise structural information regarding details of binding interactions between the substrate and the enzyme, it is difficult to pinpoint the precise origin of the differences observed in the kinetic activities.
One of the main reasons for focusing our attention on DPAn-6 derived oxylipins stems from the fact that it is a constituent of our Martek-DHA-STM Oil (27). Studies have shown that in a carrageenan-induced rat hind-paw edema model, this Martek-DHA-STM oil performed better at reducing paw-volume than the Martek-DHA-TTM (* see footnotes) oil. The major difference between the two oils is that in addition to DHA, the DHA-STM oil contains DPAn-6. We thus reasoned that DPAn-6 contributes to the anti-inflammatory activity of this oil and possibly does this via resolvin-like mediators. Since most resolvins are oxylipins produced by action of
lipoxygenases on LC-PUFAs, we examined if DPAn-6 was a substrate for lipoxygenases and characterized the products of these reactions. The major products of the most efficient reaction, 17-HDPAn-6 and 10,17-HDPAn-6 were extensively characterized and assessed for their “oral drugability” characteristics and further examined for their anti-inflammatory potential. Chemical characterization of these resolvins involved determination of double bond configurations and chirality at asymmetric carbon atoms since these are important chemical features that affect bioactivity. For example, in the NPD1 family, the major isomer produced by human leukocytes, characterized as 10(R),17(S)-dihydroxy-4Z, 7Z, 11E, 13E, 15Z, 19Z-hexaenoic acid was found to be more potent than 10(S), 17(S)- dihydroxy-4Z, 7Z, 11E, 13Z, 15E, 19Z-hexaenoic acid, in reducing neutrophil migration in a murine zymosan-induced peritonitis model(1). It should be pointed out that 18O2 incorporation experiments have shown that the former is generated via an epoxide intermediate while the latter is produced primarily via a double lipoxygenation reaction. Although another isomer, 10(S),17(S)-dihydroxy-4Z, 7Z, 11E, 13E, 15Z, 19Z-hexaenoic acid, showed substantial activity in the same study, it was not found to be biologically relevant. In our study, configurations of double-bonds in 17-HDPAn-6 and 10,17-HDPAn-6 as elucidated by high-resolution NMR were the same as analogous DHA products described by Butovich et al. (38,39). In particular, 10,17-HDPAn-6 has double bond geometry that is different from the main NPD1 isomer found in human neutrophils and is in effect consistent with a double lipoxygenation product, the major isomer in murine exudates and a minor isomer in human leukocytes as described by Serhan et al. (1,39).
Soybean lipoxygenase is known to primarily produce LC-PUFA hydroperoxides with S-configuration at the chiral ω−6 carbon. This has been seen with several substrates such as docosahexaenoic acid, arachidonic acid as well as linoleic acid when intact soybean lipoxygenase (Type 1-B) was used (38,55). Serhan et al. have demonstrated that 17(S)-HDHA is the main product of the reaction of DHA with soybean lipoxygenase and that in order to obtain 17(R)-hydroxylated compounds of DHA, one needs to use acetylated COX-2 (3,4). Our chiral
chromatography data clearly shows that DPAn-6 is converted by soybean lipoxygenase to 17(S)-HDPAn-6. Commonly used techniques, such as VCD that are used to determine configurations at chiral centers did not work for 17-HDPAn-6. This is primarily because this class of molecules is highly flexible resulting in multiple conformations thus complicating the assignment of VCD/Infrared spectra to a single conformer. Formation of 10,17-HDPAn-6 as described before seems to occur through a double lipoxygenation mechanism and we thus believe that this dihydroxy compound possesses the S configuration at C-17 and C-10, a situation analogous to what is seen for 10,17-HDHA described by Butovich et al.
Oral drugability of these two DPAn-6 derived resolvins can be evaluated using the commonly used Lipinski’s rule of five (56-58). Based on this rule, a good orally-administered drug candidate should have the following features: molecular weight less than 500, less than five hydrogen bond donors, less than ten hydrogen bond acceptors, and a partition coefficient, logP less than 5 (58). The two compounds, 17-HDPAn-6 and 10,17-HDPAn-6 satisfy all the criteria except that their logP values are 6.32 and 5.09 respectively. In spite of this apparently high hydrophobicity, the solubility of these compounds was better than a large number of other commonly used drugs such as simvastatin, tamoxifen, haloperidol as well as phenytoin. Nevertheless, the logP values of both DPAn-6 derived resolvins could be easily changed with suitable derivitization.
17-HDPAn-6 and 10,17-HDPAn-6 used in efficacy testing were produced biogenically using soybean 15-lipoxygenase and each was highly purified (>98% purity), assuring that the responses seen in the animal studies were indeed due to these specific DPAn-6 resolvins. In the air pouch model of acute inflammation, both 17-HDPAn-6 and 10,17-HDPAn-6 were highly efficacious at reducing leukocyte migration into inflamed pouches. The 100-ng DPAn-6 resolvin dose, chosen to match doses used by Serhan and colleagues with DHA-resolvins in the same model, reduced leukocyte migration by 70-80% and had similar effects to that reported for 17S-series DHA-derived resolvins which reduced neutrophil migration into air pouches (3,4). In our experiment, the 17-HDPAn-6 resolvins was more
efficacious than the same dose of 17S-HDHA, although different stereoisomers of the resolvins may have different potencies (1). Importantly, both DPAn-6 resolvins reduced leukocyte migration to the baseline levels seen in animals not receiving TNFα, and both compounds were as efficacious as the indomethacin administered intraperitoneally but at a 400-times higher dose (on a whole animal basis). Interestingly, both compounds proportionately reduced granulocyte and increased macrophage numbers. This is consistent with a pro-resolution mechanism described by Gilroy et al (59) wherein neutrophil migration is reduced and macrophages move in to phagocytose the apoptotic neutrophils. Further research is required to understand the specific mechanism by which the DPAn-6 resolvins mediate their response, but in the air pouch model of acute inflammation, they behave similarly to the structurally analogous DHA-derived resolvins.
The hind paw edema model is a widely used model of acute inflammation, and has been recently used to test the analgesic effects of lipoxins (60). In our studies, paw inflammation was induced by injecting crosslinked carrageenan. Despite this strong stimulus, both 17-HDPAn-6 and 10,17-HDPAn-6 significantly reduced paw edema by 20-25% when administered systemically using a 5-µg intravenous dose (approximately 0.025 mg/kg). This response was similar to the response to biogenically synthesized 17S-HDHA, also administered intravenously. Both compounds also showed efficacy at early time points (2 hours post carrageenan) when administered orally at the lowest dose (2.5 µg) tested. However, both compounds exhibited non-monotonic dose response behavior with the oral administration route. The 17-HDPAn-6 for example was not
active at the mid 25-µg dose (similar to its DHA analog 17-HDHA), but had activity at the low and high doses. The most effective doses across all time points, resulting in about 25% reduction in edema, were 250 µg for 17-HDPAn-6 and 25 µg for 10,17-HDPAn-6. These observations suggest that either 10,17-HDPAn-6 is more potent than 17-HDPAn-6, that bioactive metabolites of 10,17-HDPAn-6 contribute to its response, or that early exposure to 10,17-HDPAn-6 may result in extended effects, by for example altering gene expression patterns. Although we do not know the reason for the non-monotonic dose response behavior observed here, possible explanations include dose-dependent metabolism in vivo, interaction with multiple receptors systems or mixed agonist/antagonist activity profiles (61,62). Based on strong similarities to the DHA-derived resolvins, in both their synthesis by lipoxygenases to structurally analogous compounds, and their comparable activity at similar doses in acute inflammation models, these DPAn-6-derived oxylipins appear to function like resolvins which act in a pro-resolution fashion to down regulate inflammation and can thus be categorized as DPAn-6 derived resolvins. Further studies will be required to determine whether persistent, inappropriate disease-associated inflammation, such as that found in cardiovascular disease or autoimmune diseases, can be modified by providing either DPAn-6 fatty acid precursors or by direct administration of these DPAn-6-derived resolvins or analogs thereof. Although a large number of studies need to be done to assess the bio-efficacy and therapeutic profile of both 17-HDPAn-6 and 10,17-HDPAn-6, these could potentially represent a new class of therapeutic resolvins.
REFERENCES
1. Serhan, C. N., Gotlinger, K. H., Hong, S., Lu, Y., Siegelman, J., Baer, T., Yang, R., Colgan, S. P., and Petasis, N. A. (2006) The Journal of Immunology 176, 1848-1859
2. Serhan, C. N., Clish, C. B., Brannon, J., Colgan, S. P., Chiang, N., and Gronert, K. (2000) J. Exp. Med. 192, 1197-1204
3. Hong, S., Gronert, K., Devchand, P. R., Moussignac, R., and Serhan, C. N. (2003) The Journal of Biological Chemistry 278, 14677-14687
4. Serhan, C. N., Hong, S., Groner, K., Colgan, S. P., Devchand, P. R., Mirick, G., and Moussignac, R. L. (2002) J. Exp. Med. 196, 1025-1037
5. Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R., Mirick, G., and Moussignac, R. L. (2002) J. Exp. Med. 196, 1025-1037
6. Farooqui, A. A., Horrocks, L. A., and Farooqui, T. (2007) J. Neurochem.
7. Maderna, P., Godson, C., Hannify, G., Murphy, M., and Brady, H. R. (2000) Am. J. Physiol. Cell. Physiol. 279, C945-953
8. Kieran, N. E., Maderna, P., and Godson, C. (2004) Kidney Int. 65, 1145-1154 9. Bonnans, C., Chanez, P., and Chavis, C. (2004) Allergy 59, 1027-1041 10. Levy, B. D., De Sanctis, G. T., Devchand, P. R., Kim, E., Ackerman, K., Schmidt, B., Szczeklik,
W., Drazen, J. M., and Serhan, C. N. (2003) Adv. Exp. Med. Biol. 525, 19-23 11. Serhan, C. N., Hamberg, M., and Samuelsson, B. (1984) Proc. Natl. Acad. Sci. U S A 81, 5335-
5339 12. Serhan, C. N. (2005) Curr. Opin. Clin. Nutr. Metab. Care 8, 115-121 13. Samuelsson, B., Dahlen, S. E., Lindgren, J. A., Rouzer, C. A., and Serhan, C. N. (1987) Science
237, 1171-1176 14. Serhan, C. N. (2002) Prostaglandins Other Lipid Mediat. 68-69, 433-455 15. Guilford, W. J., and Parkinson, J. F. (2005) Prostaglandins Leukot. Essent. Fatty Acids 73, 245-
250 16. Levy, B. D. (2005) Prostaglandins Leukot. Essent. Fatty Acids 73, 231-237 17. Serhan, C. N. (2006) Anesthesiol. Clin. 24, 341-364 18. Arita, M., Yoshida, M., Hong, S., Tjonahen, E., Glickman, J. N., Petasis, N. A., Blumberg, R. S.,
and Serhan, C. N. (2005) Proc. Natl. Acad. Sci. U S A 102, 7671-7676 19. Hasturk, H., Kantarci, A., Ohira, T., Arita, M., Ebrahimi, N., Chiang, N., Petasis, N. A., Levy, B.
D., Serhan, C. N., and Van Dyke, T. E. (2006) The FASEB Journal 20, 401-403 20. Calder, P. C. (2006) Am. J. Clin. Nutr. 83, 1505S-1519S 21. Hong, S., Lu, Y., Yang, R., Gotlinger, K. H., Petasis, N. A., and Serhan, C. N. (2006) J. Am. Soc.
Mass. Spectrom. 22. Bazan, N. G. (2005) Brain Pathol. 15, 159-166 23. Mukherjee, P. K., Marcheselli, V. L., Serhan, C. N., and Bazan, N. G. (2004) Proc. Natl. Acad.
Sci. U S A 101, 8491-8496 24. Phillis, J. W., Horrocks, L. A., and Farooqui, A. A. (2006) Brain Res. Rev. 52, 201-243 25. Gardner, H. W. (1991) Biochim. Biophys. Acta 1084, 221-239 26. Piazza, G. J. (1996) AOCS Press 27. Green, K. N., Martinez-Coria, H., Khashwji, H., Hall, E. B., Yurko-Mauro, K. A., Ellis, L., and
LaFerla, F. M. (2007) J. Neurosci. 27, 4385-4395 28. Akiba, S., Murata, T., Kitatani, K., and Sato, T. (2000) Biol. Pharm. Bull. 23, 1293-1297 29. Murphy, M. G., Wright, V., Scott, J., Timmins, A., and Ackman, R. G. (1999) Lipids 34, 115-124 30. Murphy, M. G., Wright, V., Ackman, R. G., and Horackova, M. (1997) Mol. Cell Biochem. 177,
257-269 31. Tsuji, M., Murota, S. I., and Morita, I. (2003) Prostaglandins Leukot. Essent. Fatty Acids 68,
337-342 32. Shimizu, T., Honda, Z., Miki, I., Seyama, Y., Izumi, T., Radmark, O., and Samuelsson, B. (1990)
Methods Enzymol. 187, 296-306 33. Schilstra, M. J., Veldink, G. A., and Vliegenthart, J. F. (1994) Lipids 29, 225-231 34. Berry, H., Debat, H., and Larreta-Garde, V. (1997) FEBS Lett. 408, 324-326 35. Sangster, J. (1997) Octanol-water partition coefficients: Fundamentals and physical chemistry,
John Wiley and Sons 36. Edwards, J. C., Sedgwick, A. D., and Willoughby, D. A. (1981) J. Pathol. 134, 147-156 37. Winter, C. A., Risley, E. A., and Nuss, G. W. (1962) Proc. Soc. Exp. Biol. Med. 111, 544-547 38. Butovich, I. A., Lukyanova, S. M., Bachmann, C. (2006), J. Lipid Res. 47(11), 2462-2474 39. Butovich, I. A. (2006) J. Lipid Res. 47 (4), 854-863 40. Bayer, M., Monsandl, A, Thaci, D. (2005) Journal of Chromatography B 819, 323-328 41. Brash, A. R., and Boeglin. (2000) Anal. Biochem. 287 42. Kuhn, H., Walther, M., and Kuban, R. J. (2002) Prostaglandins Other Lipid Mediat. 68-69, 263-
43. Hamberg, M., and Samuelsson, B. (1967) J. Biol. Chem. 242, 5329-5335 44. Butovich, I. A., Hamberg, M., and Radmark, O. (2005) Lipids 40, 249-257 45. Careaga, M. M., and Sprecher, H. (1984) J. Biol. Chem. 259, 14413-14417 46. Aveldano, M. I., and Sprecher, H. (1983) J. Biol. Chem. 258, 9339-9343 47. Arterburn, L., Hall, E., and Oken, H. (2006) Am. J. Clin. Nutr. 83, 1467S-1476S 48. Burdge, G. C., and Wootton, S. A. (2002) Br. J. Nutr. 88, 411-420 49. Stark, K. D., Lim, S. Y., and Salem, N., Jr. (2007) Lipids Health Dis 6, 13 50. Greiner, R. S., Catalan, J. N., Moriguchi, T., and Salem, N., Jr. (2003) Lipids 38, 431-435 51. Moriguchi, T., Lim, S. Y., Greiner, R., Lefkowitz, W., Loewke, J., Hoshiba, J., and Salem, N., Jr.
(2004) J. Lipid Res. 45, 1437-1445 52. Moriguchi, T., Loewke, J., Garrison, M., Catalan, J. N., and Salem, N., Jr. (2001) J. Lipid Res.
42, 419-427 53. Schilstra, M. J., Veldink, G. A., and Vliegenthart, J. F. (1993) Biochemistry 32, 7686-7691 54. Namani, T., Ishikawa, T., Morigaki, K., and Walde, P. (2007) Colloids Surf. B Biointerfaces 54,
118-123 55. Kuhn, H., Wiesner, R., Lankin, V. Z., Nekrasov, A., Alder, L., and Schewe, T. (1987) Anal.
Biochem. 160, 24-34 56. Viswanadhan, V. N., Balan, C., Hulme, C., Cheetham, J. C., and Sun, Y. (2002) Curr. Opin.
Drug. Discov. Devel. 5, 400-406 57. Lipinski, C. A. (2000) J. Pharmacol. Toxicol. Methods 44, 235-249 58. Lipinski, C., Lombardo, F., Dominy, B., and Feeney, P. (1997) Adv. Drug Del. Rev. 46, 3-26 59. Gilroy, D. W., Lawrence, T., Perretti, M., and Rossi, A. G. (2004) Nature Reviews 3, 401-416 60. Svensson, C. I., Zattoni, M., and Serhan, C. N. (2007) J. Exp. Med. 204, 245-252 61. Kohn, M. C., and Melnick, R. L. (2002) J. Mol. Endocrinol. 29, 113-123 62. Conolly, R. B., and Lutz, W. K. (2004) Toxicol. Sci. 77, 151-157 FOOTNOTES We would like to thank Dr. Sandip Sur (NMRServices, Rochester, NY) for expert technical assistance, Dr. Dutt Vinjamoori, Dr. Paul Zimmer and Marcia Morton for helpful discussions. Unpublished observations cited in this paper are as listed below.
• Nauroth, J. M., Liu, Y. C., Van Elswyk, M., Bell, R., Bailey-Hall E., Chung, G., and Arterburn, L.M., “Anti-inflammatory Activity of Algal Oils Containing Omega-3 Docosahexaenoic Acid (DHA) and Omega-6 Docosapentaenoic Acid (DPAn-6)”, manuscript in preparation. Preliminary work pertaining to this publication has been presented at the 94th Annual Meeting of the American Association of Immunologists, 2007 (Abstract available in Journal of Immunology, 2007, 178: 101.5).
FIGURE LEGENDS
Fig. 1. Comparison of DHA, DPAn-3 and DPAn-6 as substrates for soybean lipoxygenase. Fatty acids (-○- DHA, -- DPAn-3, -▲- DPAn-6) at a concentration of 100 µM were incubated with enzyme at 0 ºC, as described in Experimental Procedures. Absorbance at 237 nm was used to estimate the amount of product formed and theoretical 100% conversion was calculated based on an extinction coefficient of 28,000 /M.cm in all three cases. The percentage conversions were verified by LC/MS. The graph shows results from replicate measurements. Error bars represent ranges. Fig. 2. Enzyme Kinetics Measurements and curve fits for DPAn-6, DPA n-3 and DHA. The reaction was carried out at 22 ºC with 39.8 U/ml of the enzyme, 4.52 X 10-3 % (v/v) Tween 20 in oxygen saturated 0.05 M sodium borate buffer (pH 9.0) and products quantified by measuring absorbance at 236 nm. Actual (●) and predicted (trace) hydroperoxide formation rates as a function of substrate concentration for
DPAn-3 (A), DPAn-6 (B) and DHA (C). Actual results are averages of triplicates, presented with standard error bars. Fig. 3. LC profile of the gram-scale reaction of DPAn-6 with soybean 15-lipoxygenase.DPAn-6 was incubated with soybean lipoxygenase in 0.05M sodium borate buffer at 4 ºC for 30 minutes. Products were reduced with sodium borohydride, reaction acidified and then extracted using DSC-18 material. Products were analyzed by LC/MS as described in Experimental procedures. A, Total Ion chromatogram; B, UV absorbance at 236 nm; C, UV absorbance at 270 nm. Fig. 4. LC/MS/MS of purified 17-HDPAn-6 and 10,17-HDPAn-6. Reaction mixture represented by Figure 2 was purified by preparatory HPLC techniques using conditions described under Experimental Procedures. Fractions of interest were pooled from several runs and further concentrated and analyzed for purity using LC/MS/MS techniques. A, Total ion chromatogram of 17-HDPAn-6 with LC conditions as described in Experimental Procedures. The inset shows the UV spectrum of the main peak; B, Mass Spectra of the main peak shown in A with main fragments denoted by their origin. The inset shows 17-HDPAn-6 with expected diagnostic fragments; C, Total ion chromatogram of 10, 17-HDPAn-6 with an inset showing the UV spectrum of the main peak; D, Mass Spectra of the main peak shown in C with main fragments denoted by their origin. The inset shows 10,17-HDPAn-6 with expected diagnostic fragments; Fig. 5. NMR data for 17-HDPAn-6. A, 1D-1H spectrum showing 1H assignments. The C(17)-H-OH and the C(1)-COOH protons are not seen due to exchange broadening and thus the main peaks can be integrated to 32 protons. Any extra peaks are solvent related; B, A quantitative 1D-13C spectrum showing 13C assignments. Peaks can be integrated to 22 Carbon atoms. Any extra peaks are solvent related. Tetramethylsilane (TMS) peak was used for referencing; C, 2D-1H-1H-COSY showing correlations between cross-peaks belonging to adjacent Carbon atoms. Fig. 6. NMR data for 10,17-HDPAn-6. A, 1D-1H spectrum showing 1H assignments. The C(10)-H-OH, C(17)-H-OH and the C(1)-COOH protons are not seen due to exchange broadening and thus the main peaks can be integrated to 31 protons. Any extra peaks are solvent related; B, A quantitative 1D-13C spectrum showing 13C assignments. Peaks can be integrated to 22 Carbon atoms. Any extra peaks are solvent related. Tetramethylsilane (TMS) peak was used for referencing; C, 2D-1H-1H-COSY showing correlations between cross-peaks belonging to adjacent Carbon atoms. Fig. 7. Chirality determination of C17 in 17-HDPAn-6. 17-HDHA and 17-HDPAn-6 prepared enzymatically using 15-lipoxygenase were oxidized to the corresponding oxo-compounds and then reduced with sodium borohydride to the corresponding racemic mixtures. Separations were performed on Chiralpak-IA using methanol/water, (80:20) as mobile phase at a flow rate of 0.6 ml/minute at 25 ºC. A. Racemic 17-HDHA prepared by oxidation-reduction of enzymatically prepared 17-HDHA; B. 17S-HDHA from Cayman Chemicals; C. 17-HDHA prepared enzymatically using 15-lipoxygenase; D. Racemic 17-HDPAn-6 prepared by oxidation-reduction of enzymatically prepared 17-HDPAn-6; E. Enzymatically prepared 17-HDPAn-6 showing the major isomer assigned as “S”. Fig. 8. Predicted logD and solubility profile of 17-HDPAn-6 and 10,17-diHDPAn-6. logD and solubility were calculated for 17-HDPAn-6 and 10,17-HDPAn-6 using ACDLabs software. A. A plot of predicted logD at various pH values for 17-HDPAn-6(-○-) and 10,17-HDPAn-6 (-▲-); B. Predicted log solubility at various pH values for 17-HDPAn-6(-○-) and 10,17-HDPAn-6 (-▲-). Fig. 9. Effects of 17-HDPAn-6 and 10,17-HDPAn-6 on Leukocyte Migration in a Murine Air Pouch Model of Acute Inflammation. Figure shows means (n=10 animals per group, ± SD of number of leukocytes found in air pouch exudates 4 hrs after stimulation with TNFα. Test compounds (100 ng)
were administered intrapouch immediately before injection of the TNFα into the pouch, and indomethacin was administered i.p. (2 mg/kg) 30 minutes prior to the TNFα injection. Groups were compared to the TNFα control group by ANOVA with Dunnett’s post test; * p < 0.01 compared to TNFα control. Fig 10. Kinetics of Effect of Intravenously and Orally Administered DPAn-6 Resolvins on Carrageenan-induced Hind Paw Edema in Rats. Animals were treated with 5 µg of resolvins intravenously 2 minutes prior to carrageenan challenge (A) and 25 µg resolvins orally, 30 minutes prior to carrageenan challenge (B). Vehicle (--○--) was administered intravenously 2 minutes prior to carrageenan challenge and indomethacin (X) was dosed at 5 mg/kg intraperitoneally 30 min prior to carrageenan challenge in both (A) and (B). Resolvins shown are 17-HDPAn-6, (■), 10,17-HDPAn-6 (●), 17-HDHA (▲) in both (A) and (B) . Means (n=8 animals per group) ± SD of edema volume measured 2, 4, 6 or 24 hours post carrageenan challenge are shown. ** Significantly different than vehicle control by ANOVA with Dunnett’s post test, p < 0.01. Fig. 11. Dose Effects of 17-HDPAn-6 and 10,17-HDPAn-6 on Carrageenan-induced Rat Paw Edema. All compounds were administered by oral gavage 30 min before carrageenan challenge, and paw edema was measured 2, 4, or 6 hr after carrageenan challenge. Figure shows mean paw edema volume (n = 6 animals/group) ± SD after administration of various doses of 17-HDPAn-6 (A) or 10,17-HDPAn-6 (B). Groups represented are vehicle (○), 2.5 µg (●), 25 µg (■), 250 µg(▲). Dose effects of compounds at the 4-hr time point are shown in panel C. Resolvin treatment groups were compared with vehicle control, * p < 0.05 and ** p < 0.01 by ANOVA with Dunnett’s post test.
Table 1. Kinetic parameters of PUFA substrates with 15-lipoxygenase. Substrates (5-100 µM) were incubated with 39.8 U/ml of 15-lipoxygenase, 4.52 X 10-3 % (v/v) Tween 20 in oxygen saturated 0.05 M sodium borate buffer (pH 9.0) and products quantified using absorbance at 236 nm. Curve fits were created using the Michaelis-Menten model. DPAn-3 DPAn-6 DHA Vmax (µM/min) 672.9±31.8 487.1±13.9 481.9±21.4 Km (µM) 36.2±4.1 14.3±1.5 20.4±2.8 Vmax/Km (/min) 18.6±2.3 34.1±3.7 23.6±3.4 R2 0.93 0.90 0.85
Table 2. Products formed on incubation of DHA, DPAn-3 and DPAn-6 with soybean 15-lipoxygenaseDHA, DPAn-3 and DPAn-6 were incubated with soybean 15-lipoxygenase in 0.05 M sodium borate buffer, pH 9.0, at a concentration of 100 µM, at 4 ºC for 30 minutes and products reduced to the corresponding hydroxy compounds using sodium borohydride. Reactions were analyzed and product structures elucidated based on LC-MS/MS analysis of diagnostic fragments. Diagnos-tic fragments which helped in ascertaining positions of hydroxylation are shown in parentheses.
Table 3. Products formed on incubation of DHA, DPAn-3 and DPAn-6 with porcine 12-lipoxygenaseDHA, DPAn-3 and DPAn-6 were incubated with 12-lipoxygenase obtained from porcine leukocytes in 0.1 M Tris-HCl, pH 7.5, 5 mM EDTA and 0.03% Tween-20, at a concentration of 100 µM, at 4 ºC for 30 minutes and products reduced to the corresponding hydroxy compounds using sodium borohydride. Reac-tions were analyzed by LC-MS/MS and product structures elucidated based on analysis of diagnostic fragments. Diagnostic fragments which helped in ascertaining positions of hydroxylation are shown in parentheses.
Table 4. Products formed on incubation of DHA, DPAn-3 and DPAn-6 with potato 5-lipoxygenase
+H-H
181153
+H
+H
+H
-H
-H
-H+H
+H
-H149
-H149
165
193
233261
181
301
153
206
221
+H 167
+H-H
183155
+H-H
181153
+H-H
195
223
+H -H235263
DHA, DPAn-3 and DPAn-6 were incubated with potato 5-lipoxygenase in 0.05 M Na-MES buffer, pH 6.3, 100 µM and 0.02% C12E10 at a concentration of 100 µM, at 4 ºC for 30 minutes and products reduced to the corresponding hydroxy compounds using sodium borohydride. Reactions were analyzed by LC-MS/MS and product structures elucidated based on analysis of diagnostic fragments. Diagnostic fragments which helped in ascertaining positions of hydroxylation are shown in parentheses.
Table 5. Proportion of Granulocytes and Macrophages in Exudates Harvested from Murine Air Pouches. Animals were injected with 100 ng of resolvins followed immediately by 100 ng TNFα intrapouch. Exudates were harvested 4 hrs later and granulocytes and macrophages were quantified after Diff-Quik staining on slides. Means ± SD are shown. Significantly different than TNFα control by Student’s t test, *p<0.05, ** p < 0.01.
